Small ubiquitin-related modifier (SUMO) can be covalently attached to target proteins and thereby plays a crucial role in regulating the normal functions of cells, such as protein-protein interaction, subcellular localization, DNA repair, cell cycle and transcription factor regulation. Several lines have implicated that sumoylation is important in disease occurrence and development. This brief review will focus on some recent findings about the roles of sumoylation in the etiology and treatment of hematological malignancies.
Animals ; Hematologic Diseases ; pathology ; therapy ; Humans ; Sumoylation

Fertility ; Hematologic Diseases/therapy* ; Hematologic Neoplasms/therapy* ; Hematopoietic Stem Cell Transplantation ; Humans

Hematologic Diseases ; drug therapy ; Hepcidins ; therapeutic use ; Homeostasis ; Humans ; Iron

Pathologic splenic rupture is an uncommon finding associated with a long list of pathologic conditions, including infectious diseases, hematologic diseases, metabolic disorders, drug therapy, primary and secondary benign or malignant splenic tumors, acute or chronic pancreatitis, collagen disorders pregnancy, and others. In this report, we present a case study of a pathologic splenic rupture caused by metastasis from a previously undiagnosed gastric carcinoma.
Collagen ; Communicable Diseases ; Drug Therapy ; Hematologic Diseases ; Neoplasm Metastasis ; Pancreatitis, Chronic ; Pregnancy ; Splenic Rupture*

In recent years, with the development of gene editing technology, the site-specific genome can be modified. The curability of genetic disease may be achieved by the use of gene editing techniques. As the simplicity, high specificity and economical efficiency, much attention has been paid to the CRISPR/Cas9 system, which was been widely used in research of molecular biology and other fields of life science. In this review, the mechanism for CR1SPR/Cas9 system and the progress of gene therapy, such as for hemophilia, betathalassaemia and chronic myeloid leukemia were summarized briefly.
CRISPR-Cas Systems ; Gene Editing ; Genetic Therapy ; Hematologic Diseases ; therapy ; Humans ; Molecular Biology

PURPOSE: The purpose of this study is to identify the prevalence of attention-deficit hyperactivity disorder (ADHD) among children treated for childhood malignant hematologic diseases, and determine the different characteristics of the patients with ADHD as opposed to the patients without ADHD, which will help to predict the development of ADHD and to help treat them. METHODS: 172 patients diagnosed as childhood malignant hematologic diseases went through the test battery including diagnostic criteria for ADHD in pediatric neurology department of Seoul St. Mary's hospital from March 2009 to May 2012. Age, sex, ADHD type, hematologic diseases type, age at onset of hematologic diseases, treatment with/without chemotherapy and relapse were investigated. These data were compared between the groups of the patients without ADHD and with ADHD. RESULTS: Out of 172 patients, Fifty one patients (29.6%) had both ADHD and childhood malignant hematologic diseases. Sex (male), age at onset of hematologic diseases (< or =5 years) and treatment(with chemotherapy) was significantly higher in the patients with ADHD than the patients without ADHD (P<0.05). Male had about 2.9 fold increased risk for ADHD compared to female (P=0.005). The patients < or =5 years of age at onset had about 3.3 fold increased risk for ADHD compared to the patients > or =11 years (P=0.007). The patients with chemotherapy had about 3.4 fold increased risk for ADHD compared to the patients without chemotherapy (P=0.023). CONCLUSION: This study showed childhood malignant hematologic disorders has significant correlation with ADHD. In addition, Male, < or =5 years of age at onset and use of chemotherapy in the patients can be necessary to predict ADHD. Therefore, early detection and establishment of the countermeasures for ADHD are necessary.
Attention Deficit Disorder with Hyperactivity* ; Child ; Drug Therapy ; Female ; Hematologic Diseases* ; Humans ; Male ; Neurology ; Prevalence ; Recurrence ; Seoul

BACKGROUND: The automated hematologic analyzer has increased the precision and accuracy for platelet counting. However, spurious elevations of automated platelet counts occur occasionally in patients receiving chemotherapy or radiotherapy for solid organ tumors, leukemia, and other lymphomas. The CELL-DYN Sapphire analyzer (Abbott, USA) detects platelets with a CD61 monoclonal antibody and uses both impedance and optical technologies; thus, it is expected to present more accurate platelet counts. METHODS: We evaluated platelet counts obtained with the CELL-DYN Sapphire impedance, optical, and CD61 methods and compared them with the results obtained with the XE-2100 analyzer (Sysmex, Japan). We analyzed 111 samples from hospitalized patients with various hematologic diseases, who were receiving chemotherapy or radiotherapy. RESULTS: The results from the impedance, optical, and CD61 methods of CELL-DYN Sapphire and those from XE-2100 showed significant linearity, with correlation coefficients greater than 0.99. Three cases had significantly different platelet counts among the different methods used. Microscopic examination of these three cases showed very low platelet counts that corresponded with the low counts from the CD61 methods. It should be noted that because the automated blood counter assesses cell populations by their dimensions, many cellular fragments that were of the same size or smaller than platelets were thus counted as platelets. CONCLUSIONS: The CELL-DYN Sapphire analyzer has good precision, linearity and performance, comparable with the XE-2100 analyzer. As the CD61 methods of CELL-DYN Sapphire is specific for platelet, this method may reduce the interference from other blood components and count the exact platelet numbers.
Aluminum Oxide* ; Blood Platelets ; Drug Therapy* ; Electric Impedance ; Hematologic Diseases* ; Humans ; Leukemia ; Lymphoma ; Platelet Count* ; Radiotherapy

Child ; Child, Preschool ; Cord Blood Stem Cell Transplantation ; methods ; Female ; Hematologic Diseases ; therapy ; Humans ; Infant ; Male

Cytomegalovirus Infections ; complications ; therapy ; Female ; Hematologic Diseases ; etiology ; Hematopoiesis ; Humans ; Infant ; Male

Blood Platelets ; Hematologic Diseases ; therapy ; Humans ; Platelet Aggregation Inhibitors ; therapeutic use